{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:31:11Z","timestamp":1793035871344,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009104","name":"Department of Health Research, India","doi-asserted-by":"publisher","award":["11013\/36\/2021-GIA\/HR"],"award-info":[{"award-number":["11013\/36\/2021-GIA\/HR"]}],"id":[{"id":"10.13039\/501100009104","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.drudis.2022.103465","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T15:52:17Z","timestamp":1670255537000},"page":"103465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches"],"prefix":"10.1016","volume":"28","author":[{"given":"Yashika","family":"Tomar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srividya","family":"Gorantla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Singhvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2022.103465_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.09.023","article-title":"Psoriasis: pathological mechanisms, current pharmacological therapies, and emerging drug delivery systems","author":"Rapalli","year":"2020","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2022.103465_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-3-7643-7724-3_2","article-title":"The pathophysiology of psoriasis","author":"Newman","year":"2008","journal-title":"Treat. Psoriasis"},{"key":"10.1016\/j.drudis.2022.103465_b0015","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","article-title":"Psoriasis and comorbid diseases: Epidemiology","volume":"76","author":"Takeshita","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1084\/jem.20080129","article-title":"Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment","volume":"206","author":"Albanesi","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2022.103465_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","article-title":"Psoriasis: a mixed autoimmune and autoinflammatory disease","volume":"49","author":"Liang","year":"2017","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJM197909063011015","article-title":"Cyclosporin A for psoriasis","volume":"301","author":"W","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2022.103465_b0035","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S1074-7613(00)00070-4","article-title":"Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12","volume":"13","author":"Oppmann","year":"2000","journal-title":"Immunity"},{"key":"10.1016\/j.drudis.2022.103465_b0040","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.3390\/ijms23116130","article-title":"Transcriptional basis of psoriasis from large scale gene expression studies: The importance of moving towards a precision medicine approach","volume":"23","author":"Krishnan","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.drudis.2022.103465_b0045","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/07853899509031956","article-title":"Genetic locus for psoriasis identified","volume":"27","author":"Bowcock","year":"1995","journal-title":"Ann. Med."},{"key":"10.1016\/j.drudis.2022.103465_b0050","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.jid.2015.12.009","article-title":"Landscape of long noncoding RNAs in psoriatic and healthy skin","volume":"136","author":"Gupta","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0055","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4049\/jimmunol.1202695","article-title":"MicroRNA-31 is overexpressed in psoriasis and modulates inflammatory cytokine and chemokine production in keratinocytes via targeting serine\/threonine kinase 40","volume":"190","author":"Xu","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0060","series-title":"Delivery of Drugs","first-page":"75","article-title":"Nanocarriers for topical delivery in psoriasis","author":"Singhvi","year":"2020"},{"key":"10.1016\/j.drudis.2022.103465_b0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrmicro.2017.157","article-title":"The human skin microbiome","volume":"16","author":"Byrd","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.drudis.2022.103465_b0070","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/1346-8138.12739","article-title":"Molecular characterization of the skin fungal microbiome in patients with psoriasis","volume":"42","author":"Takemoto","year":"2015","journal-title":"J. Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0075","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/exd.13808","article-title":"The role of phosphodiesterase 4 in the pathophysiology of atopic dermatitis and the perspective for its inhibition","volume":"28","author":"Guttman-Yassky","year":"2019","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0080","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/j.molimm.2009.03.018","article-title":"The adenylyl cyclase-cAMP system suppresses TARC\/CCL17 and MDC\/CCL22 production through p38 MAPK and NF-kappaB in HaCaT keratinocytes","volume":"46","author":"Qi","year":"2009","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0085","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1080\/17425255.2016.1206886","article-title":"Pharmacodynamic assessment of apremilast for the treatment of moderate-to-severe plaque psoriasis","volume":"12","author":"Bianchi","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.drudis.2022.103465_b0090","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.biopha.2018.06.136","article-title":"Emerging landscape in psoriasis management: From topical application to targeting biomolecules","volume":"106","author":"Rapalli","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.drudis.2022.103465_b0095","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.3390\/molecules27154964","article-title":"An overview of PDE4 inhibitors in Clinical Trials: 2010 to early 2022","volume":"27","author":"Crocetti","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.103465_b0100","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jaad.2019.10.009","article-title":"Apremilast and psoriasis in the real world: A retrospective case series","volume":"83","author":"Dozier","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0105","unstructured":"LEO 32731 for the Treatment of Moderate to Severe Psoriasis Vulgaris \u2013 Full Text View \u2013 ClinicalTrials.gov. Accessed September 13, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02888236."},{"key":"10.1016\/j.drudis.2022.103465_b0110","doi-asserted-by":"crossref","first-page":"6783","DOI":"10.1096\/fj.201800354","article-title":"Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte-derived chemokine expression and neutrophil infiltration","volume":"32","author":"Lin","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.drudis.2022.103465_b0115","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s13555-019-00347-w","article-title":"Systemic treatment of psoriasis with JAK inhibitors: A review","volume":"10","author":"Kvist-Hansen","year":"2020","journal-title":"Dermatol. Ther. (Heidelb.)"},{"key":"10.1016\/j.drudis.2022.103465_b0120","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0125","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-020-01261-8","article-title":"CURRENT OPINION JAK inhibitors for treatment of psoriasis: Focus on selective TYK2 inhibitors","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2022.103465_b0130","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0135","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/intimm\/dxt062","article-title":"Tyk2 is a therapeutic target for psoriasis-like skin inflammation","volume":"26","author":"Ishizaki","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0140","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa1806382","article-title":"Phase 2 trial of selective tyrosine kinase 2 inhibition in psoriasis","volume":"379","author":"Papp","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2022.103465_b0145","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0150","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/ph13090260","article-title":"Adenosine signaling in autoimmune disorders","volume":"13","author":"Magni","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.drudis.2022.103465_b0155","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00024382-199711000-00001","article-title":"The anti-inflammatory potential of adenosine in ischemia-reperfusion injury: established and putative beneficial actions of a retaliatory metabolite","volume":"8","author":"Bouma","year":"1997","journal-title":"Shock"},{"key":"10.1016\/j.drudis.2022.103465_b0160","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1002\/jps.20745","article-title":"Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers**Cheng Yiyun and Wen Longping designed the experiments and wrote this manuscript, Man Na and other coauthors did the experiments and analyzed the da","volume":"96","author":"Yiyun","year":"2007","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.drudis.2022.103465_b0165","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.drudis.2014.02.010","article-title":"Adenosine and inflammation: What\u2019s new on the horizon?","volume":"19","author":"Antonioli","year":"2014","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.drudis.2022.103465_b0170","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/PL00012434","article-title":"Endogenous adenosine regulates neutrophil pro-inflammatory activities by cyclic AMP-dependent accelerated clearance of cytosolic calcium","volume":"51","author":"Theron","year":"2002","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.drudis.2022.103465_b0175","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nri.2016.4","article-title":"Purinergic regulation of the immune system","volume":"16","author":"Cekic","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0180","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/7019398","article-title":"The role of extracellular adenosine generation in the development of autoimmune diseases","volume":"2018","author":"Morandi","year":"2018","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.drudis.2022.103465_b0185","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1517\/13543784.2011.573785","article-title":"Investigational A3 adenosine receptor targeting agents","volume":"20","author":"Koscs\u00f3","year":"2011","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.drudis.2022.103465_b0190","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A3 adenosine receptors as modulators of inflammation: From medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.drudis.2022.103465_b0195","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1083\/jcb.106.3.761","article-title":"Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line","volume":"106","author":"Boukamp","year":"1988","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.drudis.2022.103465_b0200","unstructured":"CF101 Therapy in Patients With Moderate-to-severe Plaque Psoriasis \u2013 Full Text View \u2013 ClinicalTrials.gov. Accessed August 31, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03168256."},{"key":"10.1016\/j.drudis.2022.103465_b0205","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/nri2974","article-title":"The outs and the ins of sphingosine-1-phosphate in immunity","volume":"11","author":"Spiegel","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0210","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.drudis.2022.103465_b0215","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1126\/science.1071124","article-title":"Regulation of SREBP processing and membrane lipid production by phospholipids in Drosophila","volume":"296","author":"Dobrosotskaya","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.103465_b0220","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1084\/jem.20091619","article-title":"Lymphatic endothelial cell sphingosine kinase activity is required for lymphocyte egress and lymphatic patterning","volume":"207","author":"Pham","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.drudis.2022.103465_b0225","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1126\/science.279.5356.1552","article-title":"Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1","volume":"279","author":"Lee","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.drudis.2022.103465_b0230","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/nature09128","article-title":"Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2","volume":"465","author":"Alvarez","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.drudis.2022.103465_b0235","first-page":"809","article-title":"Sphingosine 1-phosphate signaling at the skin barrier interface","volume":"11","author":"Masuda-Kuroki","year":"2022","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.drudis.2022.103465_b0240","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0140-6736(18)30475-6","article-title":"Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study","volume":"391","author":"Kappos","year":"2018","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.drudis.2022.103465_b0245","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.4049\/jimmunol.1401842","article-title":"FTY720 abrogates collagen-induced arthritis by hindering dendritic cell migration to local lymph nodes","volume":"195","author":"Han","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0250","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.drudis.2022.103465_b0255","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1248\/bpb.b17-00939","article-title":"Validating a selective S1P 1 receptor modulator Syl930 for Psoriasis treatment","volume":"41","author":"Ji","year":"2018","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.drudis.2022.103465_b0260","unstructured":"To Assess the Effect of SCD-044 Treatment on Moderate to Severe Plaque Psoriasis \u2013 No Study Results Posted \u2013 ClinicalTrials.gov. Accessed September 1, 2022. https:\/\/www.clinicaltrials.gov\/ct2\/show\/results\/NCT04566666?view=results."},{"key":"10.1016\/j.drudis.2022.103465_b0265","unstructured":"Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis \u2013 Full Text View \u2013 ClinicalTrials.gov. Accessed September 13, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01987843."},{"key":"10.1016\/j.drudis.2022.103465_b0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","article-title":"NF-\u03baB: An essential transcription factor in psoriasis","volume":"69","author":"Goldminz","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"10.1016\/j.drudis.2022.103465_b0275","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/ni.2071","article-title":"The origins of NF-\u03baB","volume":"12","author":"Sen","year":"2011","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0280","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/nm1201-1291","article-title":"Possible new role for NF-kappaB in the resolution of inflammation","volume":"7","author":"Lawrence","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2022.103465_b0285","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1073\/pnas.89.5.1529","article-title":"Distinct combinations of NF-kappa B subunits determine the specificity of transcriptional activation","volume":"89","author":"Perkins","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2022.103465_b0290","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","article-title":"Shared principles in NF-kappaB signaling","volume":"132","author":"Hayden","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2022.103465_b0295","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a000158","article-title":"The IKK complex, a central regulator of NF-\u03baB activation","volume":"2","author":"Isra\u00ebl","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.drudis.2022.103465_b0300","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nri910","article-title":"NF-kappaB regulation in the immune system","volume":"2","author":"Li","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.drudis.2022.103465_b0305","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1111\/j.0022-202X.2005.23735.x","article-title":"Differential expression of phosphorylated NF-kappaB\/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept","volume":"124","author":"Lizzul","year":"2005","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0310","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2174\/187221309787158399","article-title":"NF-kappaB links keratinocytes and lymphocytes in the pathogenesis of psoriasis","volume":"3","author":"Tsuruta","year":"2009","journal-title":"Recent Pat. Inflamm. Allergy Drug Discov."},{"key":"10.1016\/j.drudis.2022.103465_b0315","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1346-8138.14139","article-title":"Pathogenesis of psoriasis and development of treatment","volume":"45","author":"Ogawa","year":"2018","journal-title":"J Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0320","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1111\/j.1365-2133.2005.06688.x","article-title":"A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction","volume":"152","author":"Papp","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0325","first-page":"79","article-title":"TNF-alpha inhibitors and ustekinumab for the treatment of Psoriasis: Therapeutic utility in the era of IL-17 and IL-23 inhibitors","volume":"7","author":"Hong","year":"2022","journal-title":"undefined"},{"key":"10.1016\/j.drudis.2022.103465_b0330","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque Psoriasis and psoriatic arthritis: A comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.drudis.2022.103465_b0335","unstructured":"A Study of Mirikizumab (LY3074828) in Participants With Crohn\u2019s Disease \u2013 Full Text View \u2013 ClinicalTrials.gov. Accessed September 13, 2022. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03926130."},{"key":"10.1016\/j.drudis.2022.103465_b0340","unstructured":"U.S. Food and Drug Administration. Accessed November 22, 2022. https:\/\/www.fda.gov\/."},{"key":"10.1016\/j.drudis.2022.103465_b0345","unstructured":"Home \u2013 ClinicalTrials.gov. Accessed November 22, 2022. https:\/\/clinicaltrials.gov\/."},{"key":"10.1016\/j.drudis.2022.103465_b0350","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.2147\/IJN.S247007","article-title":"Methotrexate-loaded nanostructured lipid carrier gel alleviates imiquimod-induced psoriasis by moderating inflammation: formulation, optimization, characterization, in-vitro and in-vivo studies","volume":"15","author":"Agrawal","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.drudis.2022.103465_b0355","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/ph13120484","article-title":"Apremilast microemulsion as topical therapy for local inflammation: Design, characterization and efficacy evaluation","volume":"13","author":"Sarango-Granda","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.drudis.2022.103465_b0360","first-page":"206","article-title":"Design and dermatokinetic evaluation of Apremilast loaded nanostructured lipid carriers embedded gel for topical delivery: A potential approach for improved permeation and prolong skin deposition","author":"Rapalli","year":"2021","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.drudis.2022.103465_b0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2021.117053","article-title":"Exploring the affluent potential of glyceryl mono oleate \u2013 myristol liquid crystal nanoparticles mediated localized topical delivery of Tofacitinib: Study of systematic QbD, skin deposition and dermal pharmacokinetics assessment","volume":"346","author":"Gorantla","year":"2022","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.drudis.2022.103465_b0370","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3390\/molecules27010168","article-title":"Development of sustained release baricitinib loaded lipid-polymer hybrid nanoparticles with improved oral bioavailability","volume":"27","author":"Anwer","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.drudis.2022.103465_b0375","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jsps.2019.01.012","article-title":"Nano-encapsulation and characterization of baricitinib using poly-lactic-glycolic acid co-polymer","volume":"27","author":"Ansari","year":"2019","journal-title":"Saudi Pharm. J."},{"key":"10.1016\/j.drudis.2022.103465_b0380","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13040529","article-title":"Excipient-free pure drug nanoparticles fabricated by microfluidic hydrodynamic focusing","volume":"13","author":"Arzi","year":"2021","journal-title":"Pharmaceutics"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622004585?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1359644622004585?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T13:01:49Z","timestamp":1761224509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1359644622004585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1359644622004585"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2022.103465","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2022.103465","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103465"}}